Filing Details

Accession Number:
0000903423-19-000266
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-06-28 19:02:51
Reporting Period:
2019-06-27
Accepted Time:
2019-06-28 19:02:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1743881 Bridgebio Pharma Inc. BBIO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1132625 Viking Global Performance Llc 55 Railroad Avenue
Greenwich CT 06830
No No Yes No
1133006 Andreas Ole Halvorsen 55 Railroad Avenue
Greenwich CT 06830
No No Yes No
1621596 Ltd. Master Fund Long Viking 55 Railroad Avenue
Greenwich CT 06830
No No Yes No
1621607 Viking Long Fund Gp Llc 55 Railroad Avenue
Greenwich CT 06830
No No Yes No
1621842 C. David Ott 55 Railroad Avenue
Greenwich CT 06830
No No Yes No
1711393 Sharon Rose Shabet 55 Railroad Avenue
Greenwich CT 06830
No No Yes No
1759530 Ltd. Master Equities Global Viking 55 Railroad Avenue
Greenwich CT 06830
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-06-27 11,736,137 $0.00 11,736,137 No 4 C Indirect See Explanation of Responses
Common Stock Acquisiton 2019-06-27 10,178,954 $0.00 21,915,091 No 4 C Indirect See Explanation of Responses
Common Stock Acquisiton 2019-06-27 4,705,900 $17.00 26,620,991 No 4 P Indirect See Explanation of Responses
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Explanation of Responses
No 4 C Indirect See Explanation of Responses
No 4 P Indirect See Explanation of Responses
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series C Preferred Units Disposition 2019-06-27 51,781,276 $0.00 11,736,137 $0.00
Common Stock Series D Preferred Units Disposition 2019-06-27 50,446,451 $0.00 10,178,954 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Immediately prior to the closing of the Issuer's initial public offering ("IPO"), the Series C Preferred Units and Series D Preferred Units in BridgeBio Pharma LLC held by the Reporting Persons (defined below) were exchanged for shares of common stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-6 and 16b-7.
  2. O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Long Fund GP LLC ("VLFGP") and Viking Global Opportunities GP LLC ("Opportunities GP"), the sole owner of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"). VGI provides managerial services to various investment funds, including Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund Master Ltd. ("VLFM") and Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund," and together with VLFM and VGEM, the "Viking Funds").
  3. VGP serves as the investment manager of VGEM. Opportunities Portfolio GP is the general partner of Opportunities Fund. VLFGP serves as the investment manager of VLFM. Each of the Viking Funds, VGI, VGP, VLFGP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively, the "Reporting Persons") may be deemed to beneficially own the shares reported on this form.
  4. VGEM directly holds 631,167 shares of Common Stock; VLFM directly holds 251,204 shares of Common Stock; and Opportunities Fund directly holds 25,738,620 shares of Common Stock.
  5. VGI provides managerial services to the Viking Funds. Because of the relationship between VGI and the Viking Funds, VGI may be deemed to beneficially own the shares directly held by the Viking Funds. VGP is the investment manager of VGEM. Because of the relationships between VGP and VGEM, VGP may be deemed to beneficially own the shares directly held by VGEM. VLFGP serves as the investment manager of VLFM. Because of the relationship between VLFGP and VLFM, VLFGP may be deemed to beneficially own the shares directly held by VLFM.
  6. Opportunities Portfolio GP is the general partner of Opportunities Fund. Because of the relationship between Opportunities Portfolio GP and Opportunities Fund, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock held directly by Opportunities Fund. Opportunities GP is the sole owner of Opportunities Portfolio GP. Because of the relationship between Opportunities GP and Opportunities Portfolio GP, Opportunities GP may be deemed to beneficially own the shares of Opportunities Fund.
  7. The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
  8. On June 27, 2019, the Viking Funds acquired an aggregate of 4,705,900 shares of Common Stock at a price of $17.00 per share in connection with the IPO. VGEM acquired 631,167 shares in the IPO, VLFM acquired 251,204 shares in the IPO and Opportunities Fund acquired 3,823,529 shares in the IPO.